Keyphrases
Randomized Trial
100%
Chemoprevention
100%
Colorectal Adenoma
100%
Rofecoxib
100%
Relative Risk
57%
Confidence Interval
42%
Adenoma
42%
Placebo
28%
AIMS™
14%
Risk Reduction
14%
Aspirin
14%
Upper Gastrointestinal Tract
14%
Cardioprotection
14%
Colorectal Neoplasms
14%
Thrombotic
14%
Cardiovascular Events
14%
First Year
14%
Cyclooxygenase-2
14%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
14%
Cyclooxygenase-1 (COX-1)
14%
Randomized Placebo-controlled Trial
14%
Follow-up Examination
14%
Low-dose Aspirin
14%
Aspirin Use
14%
Double-blind Trial
14%
Cyclooxygenase-2 Inhibitors
14%
Intent-to-treat Analysis
14%
Gastrointestinal Events
14%
Mantel-Haenszel Estimator
14%
Advanced Adenoma
14%
Adenoma Recurrence
14%
Recent History
14%
Chemopreventive
14%
Pharmacology, Toxicology and Pharmaceutical Science
Rofecoxib
100%
Colorectal Adenoma
100%
Adenoma
71%
Placebo
42%
Acetylsalicylic Acid
28%
Recurrent Disease
14%
Colorectal Tumor
14%
Non-Steroidal Anti-Inflammatory Drug
14%
Prostaglandin Synthase
14%
Cyclooxygenase 2
14%
COX-2 Inhibitor
14%
Neuroscience
Rofecoxib
100%
Placebo
42%
Aspirin
28%
Cyclooxygenase
14%
Non-Steroidal Anti-Inflammatory Drug
14%
Cyclooxygenase 2
14%
COX-2 Inhibitor
14%